190 related articles for article (PubMed ID: 32658485)
1. Facile Fabrication of Nanoparticles with Dual-Targeting Ligands for Precise Hepatocellular Carcinoma Therapy
Xiang Y; Huang W; Huang C; Long J; Zhou Y; Liu Y; Tang S; He DX; Tan XW; Wei H; Yu CY
Mol Pharm; 2020 Sep; 17(9):3223-3235. PubMed ID: 32658485
[TBL] [Abstract][Full Text] [Related]
2. Delivery of Liver-Specific miRNA-122 Using a Targeted Macromolecular Prodrug toward Synergistic Therapy for Hepatocellular Carcinoma.
Ning Q; Liu YF; Ye PJ; Gao P; Li ZP; Tang SY; He DX; Tang SS; Wei H; Yu CY
ACS Appl Mater Interfaces; 2019 Mar; 11(11):10578-10588. PubMed ID: 30802029
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo evaluation of macromolecular prodrug GC-FUA based nanoparticle for hepatocellular carcinoma chemotherapy.
Huang C; Li NM; Gao P; Yang S; Ning Q; Huang W; Li ZP; Ye PJ; Xiang L; He DX; Tan XW; Yu CY
Drug Deliv; 2017 Nov; 24(1):459-466. PubMed ID: 28219253
[TBL] [Abstract][Full Text] [Related]
4. Design of an Anticancer Copper(II) Prodrug Based on the Lys199 Residue of the Active Targeting Human Serum Albumin Nanoparticle Carrier.
Gou Y; Zhang Y; Zhang Z; Wang J; Zhou Z; Liang H; Yang F
Mol Pharm; 2017 Jun; 14(6):1861-1873. PubMed ID: 28471669
[TBL] [Abstract][Full Text] [Related]
5. Cytocompatible chitosan-graft-mPEG-based 5-fluorouracil-loaded polymeric nanoparticles for tumor-targeted drug delivery.
Antoniraj MG; Ayyavu M; Henry LJK; Nageshwar Rao G; Natesan S; Sundar DS; Kandasamy R
Drug Dev Ind Pharm; 2018 Mar; 44(3):365-376. PubMed ID: 28835136
[TBL] [Abstract][Full Text] [Related]
6. Targeted Nanoparticles for Co-delivery of 5-FU and Nitroxoline, a Cathepsin B Inhibitor, in HepG2 Cells of Hepatocellular Carcinoma.
Varshosaz J; Fard MM; Mirian M; Hassanzadeh F
Anticancer Agents Med Chem; 2020; 20(3):346-358. PubMed ID: 31566137
[TBL] [Abstract][Full Text] [Related]
7. A conveniently synthesized Pt (IV) conjugated alginate nanoparticle with ligand self-shielded property for targeting treatment of hepatic carcinoma.
Wang X; Chang Z; Nie X; Li Y; Hu Z; Ma J; Wang W; Song T; Zhou P; Wang H; Yuan Z
Nanomedicine; 2019 Jan; 15(1):153-163. PubMed ID: 30308299
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of Biotin-Modified Galactosylated Chitosan Nanoparticles and Their Characteristics in Vitro and in Vivo.
Cheng M; Ma D; Zhi K; Liu B; Zhu W
Cell Physiol Biochem; 2018; 50(2):569-584. PubMed ID: 30308481
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticles inhibit cancer cell invasion and enhance antitumor efficiency by targeted drug delivery via cell surface-related GRP78.
Zhao L; Li H; Shi Y; Wang G; Liu L; Su C; Su R
Int J Nanomedicine; 2015; 10():245-56. PubMed ID: 25565817
[TBL] [Abstract][Full Text] [Related]
10. Anti-tumor immune response of folate-conjugated chitosan nanoparticles containing the IP-10 gene in mice with hepatocellular carcinoma.
Lai C; Yu X; Zhuo H; Zhou N; Xie Y; He J; Peng Y; Xie X; Luo G; Zhou S; Zhao Y; Lu X
J Biomed Nanotechnol; 2014 Dec; 10(12):3576-89. PubMed ID: 26000371
[TBL] [Abstract][Full Text] [Related]
11. Improved antitumor activity and reduced cardiotoxicity of epirubicin using hepatocyte-targeted nanoparticles combined with tocotrienols against hepatocellular carcinoma in mice.
Nasr M; Nafee N; Saad H; Kazem A
Eur J Pharm Biopharm; 2014 Sep; 88(1):216-25. PubMed ID: 24813390
[TBL] [Abstract][Full Text] [Related]
12. Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery.
Wang Q; Zhang L; Hu W; Hu ZH; Bei YY; Xu JY; Wang WJ; Zhang XN; Zhang Q
Nanomedicine; 2010 Apr; 6(2):371-81. PubMed ID: 19699319
[TBL] [Abstract][Full Text] [Related]
13. In vivo tumor targeting and anti-tumor effects of 5-fluororacil loaded, folic acid targeted quantum dot system.
Bwatanglang IB; Mohammad F; Yusof NA; Abdullah J; Alitheen NB; Hussein MZ; Abu N; Mohammed NE; Nordin N; Zamberi NR; Yeap SK
J Colloid Interface Sci; 2016 Oct; 480():146-158. PubMed ID: 27428851
[TBL] [Abstract][Full Text] [Related]
14. Dual-targeting nanoparticles with core-crosslinked and pH/redox-bioresponsive properties for enhanced intracellular drug delivery.
Zhao J; Yan C; Chen Z; Liu J; Song H; Wang W; Liu J; Yang N; Zhao Y; Chen L
J Colloid Interface Sci; 2019 Mar; 540():66-77. PubMed ID: 30634060
[TBL] [Abstract][Full Text] [Related]
15. Carboxymethyl-β-cyclodextrin conjugated nanoparticles facilitate therapy for folate receptor-positive tumor with the mediation of folic acid.
Su C; Li H; Shi Y; Wang G; Liu L; Zhao L; Su R
Int J Pharm; 2014 Oct; 474(1-2):202-11. PubMed ID: 25149123
[TBL] [Abstract][Full Text] [Related]
16. Functionalized PAMAM-based Nanoformulation for Targeted Delivery of 5-Fluorouracil in Hepatocellular Carcinoma.
Chen S; Ouyang H; He D; Liu D; Wang X; Chen H; Pan W; Li Q; Xie W; Yu C
Curr Pharm Des; 2022; 28(25):2113-2125. PubMed ID: 35524673
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo evaluation of pectin-based nanoparticles for hepatocellular carcinoma drug chemotherapy.
Yu CY; Wang YM; Li NM; Liu GS; Yang S; Tang GT; He DX; Tan XW; Wei H
Mol Pharm; 2014 Feb; 11(2):638-44. PubMed ID: 24383625
[TBL] [Abstract][Full Text] [Related]
18. Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: Enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms.
Zhang YQ; Shen Y; Liao MM; Mao X; Mi GJ; You C; Guo QY; Li WJ; Wang XY; Lin N; Webster TJ
Nanomedicine; 2019 Jan; 15(1):86-97. PubMed ID: 30244085
[TBL] [Abstract][Full Text] [Related]
19. Biodistribution and biocompatibility of glycyrrhetinic acid and galactose-modified chitosan nanoparticles as a novel targeting vehicle for hepatocellular carcinoma.
Li M; Wang Y; Jiang S; Gao Y; Zhang W; Hu S; Cheng X; Zhang C; Sun P; Ke W; Wang G; Song Z; Zhang Y; Zheng QC
Nanomedicine (Lond); 2020 Jan; 15(2):145-161. PubMed ID: 31782335
[No Abstract] [Full Text] [Related]
20. Targeted delivery of microRNA-199a-3p using self-assembled dipeptide nanoparticles efficiently reduces hepatocellular carcinoma in mice.
Varshney A; Panda JJ; Singh AK; Yadav N; Bihari C; Biswas S; Sarin SK; Chauhan VS
Hepatology; 2018 Apr; 67(4):1392-1407. PubMed ID: 29108133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
